Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04971928 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04971928 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants.
The verdict
NCT04971928, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, parallel-group study to evaluate the pharmacokinetics of GSK3228836 in participants with Child-Pugh B (CP-B) cirrhosis (moderate hepatic impairment), Child-Pugh A (CP-A) cirrhosis (mild hepatic impairment) and participants with normal hepatic function as healthy control.
Interventions
- DRUG GSK3228836
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2022-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04971928
The ClinicalTrials.gov registry entry for NCT04971928 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK3228836 is the first listed.
NCT04971928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04971928 about?
NCT04971928 is a clinical study titled "Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment". This is a Phase 1, open-label, parallel-group study to evaluate the pharmacokinetics of GSK3228836 in participants with Child-Pugh B (CP-B) cirrhosis (moderate hepatic impairment), Child-Pugh A (CP-A) cirrhosis (mild hepatic impairment) and participants with normal hepatic function as healthy contro...
What is the current status of trial NCT04971928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-09-07. Estimated completion is 2022-05-12.
What interventions are being tested in trial NCT04971928?
The interventions under investigation include: GSK3228836 (DRUG).
Who is sponsoring clinical trial NCT04971928?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.